{"entity":{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of MCLA-129 and Ensartinib in advanced solid tumours, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","summary":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07448116 by Betta Pharmaceuticals Co., Ltd., with 164 participants planned, started 2026-01-31 and due to reach its primary completion in 2029-02-01. Interventions recorded: MCLA-129 and Ensartinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07448116","url":"https://clinicaltrials.gov/study/NCT07448116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mcla-129","ensartinib"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07448116","phase":"1/2","setting":"A Multi-cohort, Open-label Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Combination With Ensartinib Hydrochloride in Patients With Advanced Solid Tumors.","sponsor":"Betta Pharmaceuticals Co., Ltd.","enrolled":164,"outcomes":[]},"route":"/trials/nct07448116/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"},{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}]}}